Control Bionics Ltd. · ASX:CBL
Control Bionics — Investor Presentation (April 2026)
21 slides from Control Bionics's investor presentation, May 5, 2026
Slide 1: Empowerment Through Proven Neurotechnology
For personal use only EMPOWERMENT THROUGH PROVEN NEUROTECHNOLOGY ASX: CBL April 2026
Slide 2: Disclaimer
DISCLAIMER This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. For personal use only The information in this presentation, whether written or verbal, has been prepared without taking into account the co
Slide 3: Who is Control Bionics?
ABOUT US Who is Control Bionics? For personal use only CBL is a neurotechnology company that captures the body’s electrical signals generated by muscles and converts them into actionable data • Non-invasive neurotechnology • 9 patent families • FDA, TGA and CE mark devices CBL was founded more than
Slide 4: A Clear Path to Scale
A CLEAR PATH TO SCALE Accelerating the Transition to a Scalable Neurotechnology Platform For personal use only Strong Foundations Strategic Shift Platform for Scale • From retail → B2B distribution • Recurring revenue in large • World-class sEMG • Secured US reimbursement markets technology (20+ yea
Slide 5: One neural-signal platform. Three commercial pillars.
TECHNOLOGY One neural-signal platform. For personal use only Three commercial pillars. Control Bionics is not just a device company. The NeuroNode and NeuroStrip devices are the hardware expression of a single underlying neural-signal cloud-based technology, generating quality data deployed across m
Slide 6: One neural-signal platform, three commercial pillars
TECHNOLOGY One neural-signal platform Three commercial pillars For personal use only 25+ $40M 9 38 Years R&D Capital Patents + Global staff Invested provisionals • 25+ years R&D - refined in the hardest clinical environment: severely movement-compromised patients. Not theoretical. Deployed. • $40M+
Slide 7: Assistive Communication
For personal use only ASSISTIVE COMMUNICATION ASX: CBL
Slide 8: A $1B+ market. Less than 1% share.
ASSISTIVE COMMUNICATION A $1B+ market. Less than 1% share. A structural path to scale. For personal use only Background Patients with ALS/MND, Cerebral Palsy and progressive neurological conditions lose the ability to speak. Existing solutions, touch screens and eye-gaze cameras, often don’t provide
Slide 9: Wholesale partners in place. Revenue growing.
AAC - TRACTION Wholesale partners in place. Revenue growing. For personal use only Commercial agreements • Tobii Dynavox (#1 global player and largest in the US) – initial six-month US pilot across five states – 170 US salespeople creates scale for the NN • Strong early traction from Tobii staff and
Slide 10: Leveraging distributor sales reps to reach patients
AAC – HOW WE SCALE Leveraging 250 distributor sales reps to reach patients For personal use only we couldn't before Route to market: • Transition CBL sales staff to clinical support roles for distributors — our people become the expert layer behind their sales force • Onboard, train and support dist
Slide 11: Neurotechnology Solutions: Sports Performance and Rehabilitation
For personal use only NEUROTECHNOLOGY SOLUTIONS Sports Performance and Rehabilitation ASX: CBL
Slide 12: High-stakes decisions, no objective data. We fix that.
NEUROTECHNOLOGY SOLUTIONS High-stakes decisions, no objective data. We fix that. For personal use only The problem • Sports teams make return-to-play calls without objective neuromuscular data >$2B* >$2.2B* >$4.2B* Sports • Physio clinics manage complex rehab performance & without real-time visibili
Slide 13: Real clients, measurable outcomes
NEUROTECHNOLOGY SOLUTIONS - TRACTION Real clients Measurable outcomes For personal use only Commercial rollout underway Sports clients • Utah Prep, SEDA College, Nets on Fire, Hoop Hall — completed programmes • Australian Institute of Sport — key opinion leader, trial underway • Princeton University
Slide 14: Existing clients prove the model. Dedicated sales hires scale it.
NEUROTECHNOLOGY SOLUTIONS - HOW WE SCALE Existing clients prove the model. Dedicated sales hires scale it. For personal use only Route to market: • Finalise next 5 sporting groups for 3-month pilot — convert proof of concept to contracted revenue • Utilise existing sales staff to sign next 5 sportin
Slide 15: Platform & Medical Technology
For personal use only PLATFORM & MEDICAL TECHNOLOGY ASX: CBL
Slide 16: The platform as a commercial asset in its own right
TECHNOLOGY & RESEARCH - TRACTION The platform as a For personal use only commercial asset in its own right Beyond AAC and Neurotechnology Solutions, the Control Bionics’ neural- signal platform creates a third revenue pillar through technology partnerships, clinical research and commercialise the da
Slide 17: Apple BCI. Research partners. APIs.
TECHNOLOGY & RESEARCH: HOW WE SCALE Apple BCI. Research partners. APIs. The platform opens up. For personal use only Route to market: • Finalise Apple BCI integration for AAC distribution partner rollout • The Apple BCI transforms how NeuroNode/NeuroStrip customers interact with Apple devices throug
Slide 18: Financial Outlook
FINANCIAL OUTLOOK FY25 actuals • Revenue: A$6.1M (+15% YoY) — strongest year in company history Capital light margin • A$5.4M capital raised in FY25 For personal use only accretive growth • Cash: A$1.2 M at 31 March 2026 • Market cap: approximately A$23.5M (ASX: CBL) — as at 1 May 2026 Assistive Com
Slide 19: Leadership
LEADERSHIP Experienced operators. Deep domain expertise. Leadership Team For personal use only Jeremy Steele — Shannon Boothroyd — James Schorey — Todd Tyler— CEO & Managing Director CFO CTO (since 2005) VP North America 15 plus years in global healthcare, 20+ years in finance across ASX-listed 35 y
Slide 20: Investment Thesis
INVESTMENT THESIS Validated platform. Multiple revenue paths. For personal use only 1. 2. 3. 4. Validated platform with a Multiple revenue pathways Clear near-term catalysts Data as a differentiator genuine IP moat from one platform • 25 years R&D: 9 patents + • Wholesale volume growing • Our high-f
Slide 21: Empowerment Through Proven Neurotechnology
EMPOWERMENT THROUGH PROVEN For personal use only NEUROTECHNOLOGY Jeremy Steele — CEO & Managing Director Email: jsteele@controlbionics.com Australia: +61 433 229 470 United States: +1 (855) 831-7521 Website: www.controlbionics.com ASX: CBL